Tango Therapeutics (TNGX) Operating Margin: 2020-2025
Historic Operating Margin for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to 26.15%.
- Tango Therapeutics' Operating Margin rose 30941.00% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -165.91%, marking a year-over-year increase of 15609.00%. This contributed to the annual value of -346.09% for FY2024, which is 3351.00% down from last year.
- Per Tango Therapeutics' latest filing, its Operating Margin stood at 26.15% for Q3 2025, which was up 102.03% from -1,287.87% recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' Operating Margin registered a high of 26.15% during Q3 2025, and its lowest value of -1,287.87% during Q2 2025.
- In the last 3 years, Tango Therapeutics' Operating Margin had a median value of -525.25% in 2023 and averaged -517.92%.
- Over the last 5 years, Tango Therapeutics' Operating Margin had its largest YoY gain of 30,941bps in 2025, and its largest YoY loss of 113,918bps in 2025.
- Over the past 5 years, Tango Therapeutics' Operating Margin (Quarterly) stood at -384.60% in 2021, then slumped by 9,219bps to -476.79% in 2022, then slumped by 16,790bps to -644.69% in 2023, then slumped by 34,900bps to -993.68% in 2024, then surged by 30,941bps to 26.15% in 2025.
- Its Operating Margin stands at 26.15% for Q3 2025, versus -1,287.87% for Q2 2025 and -788.76% for Q1 2025.